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Abstract: Bifidobacteria typically represent the most abundant bacteria of the human gut microbiota
in healthy breast-fed infants. Members of the Bifidobacterium bifidum species constitute one of the
dominant taxa amongst these bifidobacterial communities and have been shown to display notable
physiological and genetic features encompassing adhesion to epithelia as well as metabolism of
host-derived glycans. In the current review, we discuss current knowledge concerning particular
biological characteristics of the B. bifidum species that support its specific adaptation to the human
gut and their implications in terms of supporting host health.
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1. General Features of the Genus Bifidobacterium
The genus Bifidobacterium belongs to the Actinobacteria phylum and this genus together with
nine other genera constitute the Bifidobacteriaceae family [1]. Currently, the genus Bifidobacterium
is comprised of 80 (sub)species, which are distributed across seven different ecological niches,
encompassing the Gastro Intestinal Tract (GIT) of humans, non-human mammals, birds, and social
insects; waste water; and the oral cavity [2,3]. Remarkably, these ecological origins may represent the
biological niche that is common to all these habitats, which is characterized by the fact that a large
number of bifidobacterial hosts are submitting their child to parental care. Thus, their ecological origins
are perhaps enabled by maternal inheritance of bifidobacterial cells. Interestingly, this supposition has
recently been corroborated by the mapping of (near) identical bifidobacterial strains in mothers and
their corresponding children (see below) [4,5].
A small number of bifidobacterial (sub)species, such as Bifidobacterium pseudolongum, Bifidobacterium
adolescentis, Bifidobacterium pseudocatenulatum, and Bifidobacterium bifidum, have been isolated from
various animal/mammalian hosts and for this reason are acknowledged as cosmopolitan bifidobacterial
taxa [6]. In contrast, other taxa like Bifidobacterium breve appear to be much less widely distributed,
perhaps due to adaptative behavior that is host-specific [6]. Among those bifidobacteria that are found
in primates, certain bifidobacterial species are commonly identified in adults, such as B. adolescentis
and B. catenulatum, while others, like B. bifidum, B. breve, and B. longum subsp. infantis, are more
typically found in the fecal samples from breast-fed infants [7]. However, there does not seem to be an
absolute infant versus adult division of bifidobacterial (sub)species. Such findings make sense from
the perspective of vertical transmission of bifidobacterial species from mother to child, which also
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encompasses adult-type species like B. adolescentis [8,9]. The different preponderance of one species
over another in the adult/newborn GIT is influenced by the different composition of the intestinal
microbiota in terms of complexity, which in turn is very much determined by host diet [10].
2. Bifidobacterial Communities of the Human Gut
Bifidobacteria rapidly colonize the gut of infants within the first weeks following birth, a
phenomenon that is believed to be driven in no small part by the bifidogenic activities of specific mother
milk-derived oligosaccharides, commonly referred to as Human Milk Oligosaccharides (HMOs).
Metagenomic-based analyses revealed a high abundance of a small number of bifidobacterial species
such as B. breve, followed by “adult-type” bifidobacterial taxa such as B. longum and B. adolescentis [11].
The level of bifidobacterial abundance in the human gut drops with aging, even if microbial profiling
experiments that are based on FISH and metagenomic analyses have predicted that their relative load
in the adult large intestine is about 4.3 ± 4.4% of total microorganisms [12,13].
In recent years, several metagenomics as well as culture-dependent investigations of the human
gut have allowed a detailed dissection of the bifidobacterial biodiversity that is present in this
environment [6,7,14–16]. Notably, such analyses revealed that the most abundant and prevalent
bifidobacterial taxa existing in the human colon are strains of B. breve, B. bifidum, B. longum, B. adolescentis,
B. pseudolongum, B. pseudocatenulatum, and B. animalis subsp. lactis. These studies have highlighted that
the varying composition of bifidobacterial gut communities in different individuals underline both an
inter-subject and an intra-subject variability, which is in agreement with the large inter-variability of
the overall intestinal microbiota as described previously [12,17].
Recently, detailed cataloguing of bifidobacterial communities that are present during infancy
has been performed through the sequencing of the Internally Transcribed Spacer (ITS) region of the
bifidobacterial rRNA locus, which when compared to the 16S rRNA gene, allows a substantially higher
taxonomic resolution [18]. In this study, the Hierarchical clustering that was built on bifidobacterial
community profiles that are present in infant stool samples highlighted the occurrence of four
bifidobacterial groups, i.e., bifidotypes, characterized by specific, commonly co-occurring taxa such as
B. breve, B. bifidum, B. adolescentis, or B. longum [19]. In this context, B. bifidum was demonstrated to be
an important taxon among these bifidotypes in which its occurrence correlates with numerous other
bifidobacterial species that were recovered from infant fecal samples.
Interestingly, a study that compared the fecal microbiota composition of infants that were fed
with bovine milk formula or with breast milk by 16S rRNA gene microbial profiling and qPCR
showed that both B. breve and B. bifidum abundance was greater in the feces of breast milk-fed infants
than in that of formula-fed infants [20]. Furthermore, it was observed that samples with a higher
load of bifidobacteria are characterized by the presence of B. bifidum at greater than 10% of the total
bifidobacterial population [20]. The link between the highest abundance of total bifidobacteria with
appreciable B. bifidum populations in the stools of breast milk-fed babies suggests that trophic factors
play a role in determining this association [20].
In addition, bifidobacterial communities that are present in milk samples frequently contain
strains of B. bifidum, suggesting that milk represents a key vector for vertical transmission of
bifidobacteria [19,21] (Figure 1).
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Figure 1. Schematic representation of the main properties exerted by B. bifidum in the human gut. 
Specifically, there is much evidence in the literature that shows that B. bifidum is able to interact with 
the host and with other members of gut microbiota by different mechanisms, activate the host 
immunity, adhere to gut mucosa with its extracellular structures, and metabolize host glycans, such 
as mucin. See the main text for further explanation. 
3. Maternal Inheritance of Bifidobacteria 
In recent years, bifidobacteria have been shown to be subject to mother–infant transfer via a 
vertical transmission route that seems to be operational both in human beings [4,22] as well as in 
other mammalian species [6]. The most frequently shared bifidobacterial species between mothers 
and their corresponding children are strains of B. bifidum and B. breve, which were displayed to persist 
in the human gut for up to one year of life [5]. Similar results were found in another study that aimed 
at tracing maternally inherited bifidobacterial strains [22]. These investigations involved a complex 
set of analyses such as culturomics, shotgun metagenomics, and ITS bifidobacterial profiling 
experiments [18,23–25] and resulted in the identification of B. longum subsp. longum BLOI2 and B. 
breve BBRI4, which were isolated in two mother–infant couples and were also shown to be maintained 
in the intestine of babies until six months of age [22]. Similarly, a detailed cataloguing of 
bifidobacterial communities in 25 mother–offspring couples based on ITS bifidobacterial profiling 
trials followed by cultivation experiments identified several bifidobacterial strains that occur in the 
gut of both the mother and her child and of which are also present in the matching human milk 
sample [14]. Such findings are corroborated by a similar situation in other primates and certain 
mammals, where bifidobacteria were displayed to be vertically inherited from the mother to her 
newborn and where the mother’s milk appears to constitute a key vector that drives such events [6]. 
Even if the intestinal establishment of bifidobacteria is believed to be (partially) maternally 
determined, some studies postulate that their acquisition occurs during pregnancy [21].  
The precise biological/evolutionary consequences of horizontal transfer are still obscure, 
although one may argue that according to the holobiont concept [21], the first microbial colonizers, 
which include bifidobacteria, exploit crucial physiological/immunological/metabolic functions in 
driving host development. Another important speculation that is linked to the formation of the infant 
gut microbiota is that bifidobacteria, in spite of their drop in abundance upon the weaning stage, 
carry on after their initial transmission to the infant intestine and are then preserved, though perhaps 
at very low abundances, in the large intestine of the adult to ultimately be vectored to the following 
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3. Maternal Inheritance of Bifidobacteria
In recent years, bifidobacteria have been shown to be subject to mother–infant transfer via a
vertical transmission route that seems to be operational both in human beings [4,22] as well as in
other mammalian species [6]. The most frequently shared bifidobacterial species between mothers
and their corresponding children are strains of B. bifidum and B. breve, which were displayed to persist
in the human gut for up to one year of life [5]. Similar results were found in another study that
aimed at tracing maternally inherited bifidobacterial strains [22]. These investigations involved a
complex set of analyses such as culturomics, shotgun metagenomics, and ITS bifidobacterial profiling
experiments [18,23–25] and resulted in the identification of B. longum subsp. longum BLOI2 and B. breve
BBRI4, which were isolated in two mother–infant couples and were also shown to be maintained in
the intestine of babies until six months of age [22]. Similarly, a detailed cataloguing of bifidobacterial
communities in 25 mother–offspring couples based on ITS bifidobacterial profiling trials followed by
cultivation experiments identified several bifidobacterial strains that occur in the gut of both the mother
and her child and of which are also present in the matching human milk sample [14]. Such findings
are corroborated by a similar situation in other primates and certain mammals, where bifidobacteria
were displayed to be vertically inherited from the mother to her newborn and where the mother’s milk
appears to constitute a key vector that drives such events [6]. Even if the intestinal establishment of
bifidobacteria is believed to be (partially) maternally determined, some studies postulate that their
acquisition occurs during pregnancy [21].
The precise biological/evolutionary consequences of horizontal transfer are still obscure, although
one may argue that according to the holobiont concept [21], the first microbial colonizers, which
include bifidobacteria, exploit crucial physiological/immunological/metabolic functions in driving
host development. Another important speculation that is linked to the formation of the infant gut
microbiota is that bifidobacteria, in spite of their drop in abundance upon the weaning stage, carry
on after their initial transmission to the infant intestine and are then preserved, though perhaps at
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very low abundances, in the large intestine of the adult to ultimately be vectored to the following
generation [22]. The vertical transmission events of bifidobacteria may thus represent the consequence
of long-term co-evolution between bifidobacteria and their mammalian hosts.
4. Genomics Features of the B. bifidum Species
Many bifidobacterial species have had their genomes sequenced in recent years, in particular
those that are exploited by the food industry as probiotic microorganisms [21]. In this context, genome
sequencing was performed for multiple strains belonging to the species B. animalis subsp. lactis [26,27],
B. breve [28], and B. longum subsp. longum [28]. Similarly, various strains harboring the B. bifidum taxon
have been subjected to whole genome sequencing [29], allowing comparative genomic analyses, which
has shown a closed pan-genome structure. Such in silico analyses uncovered specific genetic strategies,
allowing members of the B. bifidum species to establish and persevere in the human gut, for example
thanks to the synthesis of different types of pili [30,31] or through metabolic abilities pertaining to
host-derived glycans [29,32].
The NCBI-deposited reference genome of the B. bifidum species is that of the infant stool isolate
PRL2010 [32], which was sequenced and published in 2010. A functional classification of the genes
occuring in B. bifidum chromosomes following the Cluster of Orthologous Genes (COG) families
revealed that a large proportion (approximately 14%) are ascribed to the COG family of carbohydrate
metabolism and transport [33,34].
5. The Glycobiome of B. bifidum Species
The glycobiome represents the overall genes that are expected to be responsible for the carbohydrate
metabolism and in the B. bifidum species, consists of more than 3000 genes that encode putative
carbohydrate-active enzymes, comprising glycosyl hydrolases (GHs), glycosyl transferases (GTs), and
carbohydrate esterases (CEs). In particular, according to the Carbohydrate Active Enzymes (CAZy)
database [35], there are many genes coding members of family GH13, which are largely identified
in bifidobacterial chromosomes, commonly for those bifidobacterial strains that are identified from
the intestine of mammals. GH13 are common of bacteria and are responsible for the breakdown
of an extensive range of glycans, involving plant-derived complex carbohydrates like starch and
correlated substrates (e.g., amylose and amylopectin and/or (cyclo)maltodextrins), trehalose, stachyose,
raffinose, and melibiose [33]. Interestingly, the B. bifidum glycobiome also includes members of GH
families that are crucial in host glycan metabolisms, like those harboring GH33 and GH34, representing
exo-sialidases, GH29, and GH95, which characterize fucosidases, and GH20 involving hexosaminidase
and lacto-N-biosidase activities, which are genes that are predicted to be responsible for the metabolism
of host-glycans (see below) [34]. In this context, a comparative genomic analysis based on 15 different
strains highlighted the presence of a conserved gene set that appears to uniquely occur in B. bifidum
strains [29]. This gene set represents core genome sequences encoding various GHs that are specifically
involved in mucin breakdown, which is indicative of a nutritional acquisition strategy targeting
host-derived glycans [29].
Furthermore, an exhaustive analysis of the genetic backgrounds for carbohydrate uptake in
B. bifidum species revealed that this taxon contains a relatively small number of genes coding for
carbohydrate carriers when associated with other bifidobacterial taxa that are present in the infant
intestine, like B. breve, B. longum subsp. longum, and B. longum subsp. infantis [7,36]. In fact, only
25 genes are estimated to synthetize carrier systems in the B. bifidum PRL2010 chromosome and be
committed to glycan uptake. However, the other human gut bifidobacterial chromosomes are predicted
to encompass between 35 and 68 such genes, as characterized by B. adolescentis ATCC 15703 and B.
longum subsp. infantis ATCC 15697, respectively. This suggests that carbohydrate metabolism in
B. bifidum taxon is limited to a reasonably low amount of carbohydrates.
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6. The Ability of B. bifidum to Metabolize Host-Derived Glycans
The main carbohydrates that are produced by human beings, i.e., host-derived glycans, which
may represent a carbon source for bifidobacteria, are mucin and HMOs. Notably, these sugars are
found in the gut in high amounts during two different stages of human life, i.e., the infant period
(HMOs) and the adult life (mucin). Interestingly, the B. bifidum taxon is present during both of these
life stages, though its prevalence and abundance are higher during infancy. However, we may argue
that its occurrence in the adult gut is supported by the action of glycan substrates such as mucin
(see below).
Mucin is a glycoprotein that constitutes the key component of the mucus gel coating, which covers
the epithelial surface of the human GIT [37]. The key glycan monomers that were identified in this
glycoprotein encompass N-acetylglucosamine, N-acetylgalactosamine, fucose, galactose, and sialic
acid [38]. Notably, B. bifidum species is the only member among all the recognized Bifidobacterium
(sub)species that is capable of growth by means of mucin metabolism [32,39,40].
As mentioned before, a large portion of the predicted GH-encoding genes that were identified in the
B. bifidum PRL2010 genome represent enzymes that are estimated to be associated with the breakdown of
mucin-derived oligosaccharides, most of which are exclusively occurring in the B. bifidum genome [29].
In addition, according to the CAZy database [35], the B. bifidum PRL2010 chromosome encompasses
members of two carbohydrate-binding module (CBM) families, i.e., CBM32 and CBM51, which are
predicted to assist in binding to carbohydrates that are encountered in the mucin core structure.
Further information on how B. bifidum metabolizes mucin has been obtained from functional
genomic approaches, including proteomics- as well as transcriptomics-based analyses [32]. The
main B. bifidum enzymes that are responsible for mucin breakdown include extracellular enzymes,
like putative exo-α-sialidases, as well as a predicted 1,2-α-L-fucosidase and 1,3/4-α-L-fucosidase,
and a putative cell wall-anchored endo-α-N-acetylgalactosaminidase [41–43]. Further enzymes that
are predicted to be involved in mucin metabolism encompass N-acetyl-β-hexosaminidases and
β-galactosidases. The mucin-breakdown features of B. bifidum species is also supported by the
occurrence of glycan carriers harboring several families, like the ATP-binding cassette (ABC-type),
phosphoenolpyruvate phosphotransferase system (PEP-PTS), and major facilitator superfamily (MFS).
Specifically, the chromosome of B. bifidum PRL2010 contains a DNA region encompassing eight
genes that are predicted to code for enzymes responsible for the hydrolysis of galacto-N-biose,
which constitutes one of the key structures of mucin-oligosaccharides. The possible metabolic
scenario employed by B. bifidum PRL2010 involves the action of extracellular enzymes such
as exo-α-sialidases and 1,2-α-/α-1,3/4-L-fucosidases that are responsible for de-sialylidation and
de-fucosylation, respectively, thus allowing B. bifidum access to mucin-derived galacto-N-biose [42].
This mucin-derived substrate is then further metabolized by other enzymes coded by PRL2010 like
lacto-N-biosidase and endo-α-N-acetylgalactosaminidase [42,44,45].
Comparative genomic analyses encompassing other public accessible B. bifidum chromosomes
showed that the estimated genetic background that is responsible for mucin metabolism is well
conserved in this bifidobacterial taxon [29].
Mucin breakdown is predicted to diminish the mucin layer and, therefore, decrease the defensive
barrier of the intestinal mucosa, rendering this activity as a potentially unwanted occurrence. However,
one may also argue that mucin breakdown has evolved as a “host-settler mechanism”. In fact, mucin
synthesis in the gut typically starts upon delivery, then occurs for several months and arrives at its
mature level at about one year of life [46]. Fascinatingly, mucin metabolism as performed by B. bifidum
could activate enhanced production of mucin, thus enhancing the depth of the mucus layer wrapping
the mucosa and, thus, strengthening the epithelial barrier function [47].
7. The Capability of B. bifidum to Interact with its Host by Extracellular Structures
Commensal gut bacteria are known to establish a cross-talk with the human host through
various structures including pili, nanotubes, capsular structures, S-layers proteins, and flagella [48–51].
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Interestingly, many of these structures are also used to drive the microbe–microbe dialogue occurring
between the different players of the human gut microbiota, comprising bifidobacterial strains [52].
Recently, the genetic variety of predicted sortase-dependent pili of bifidobacteria was assessed,
allowing the construction of a bifidobacterial sortase-dependent fimbriome database [31]. Interestingly,
the identified bifidobacterial fimbrione was shown to be highly variable among the various
bifidobacterial (sub)species, possibly as a result of horizontal gene transfer events [31]. Transcriptome
experiments and binding assays involving different substrates has demonstrated the importance of
bifidobacterial pili in modulating several adhesion capabilities of bifidobacteria to glycans and to
extracellular matrix proteins [31], thus corroborating the ecological fitness of bifidobacteria in the
human intestine.
Amongst the fimbriome of members of the Bifidobacterium genus, the best experimentally and
functionally characterized sortase-dependent pili are those of B. bifidum PRL2010 [30,53,54]. Such
extracellular structures are composed of major and minor subunits, which are covalently assembled
through the action of a sortase. These proteins are typically encoded by three adjacent genes, referred
to as a sortase-dependent pilus locus. The genome of B. bifidum PRL2010 includes three distinct
sortase-dependent pilus loci of which only two were predicted to be genetically intact, while the third
appears to be non-functional due to a frameshift within the coding region of the gene encoding major
pilus subunit [55].
Microarray-mediated transcriptome analysis of B. bifidum PRL2010 following murine colonization
and following interaction with human cell lines revealed a significant increase in the transcription of
the genes including two sortase-dependent pili, named pil2 and pil3 [55]. Heterologous expression of
pil2 and pil3 in the non-piliated Lactococcus lactis demonstrated that both pili are promoting adhesion to
human gut mucosa by extracellular matrix (ECM) proteins. ECM de-glycosylation triggered a drastic
drop in PRL2010 pilus-based binding ability compared to untreated ECM [55], suggesting that N-
and/or O-linked glycoproteins are involved in the adhesion of B. bifidum PRL2010 pili to ECM.
Recombinant piliated L. lactis cells were also displayed to induce an increased tumor necrosis
factor alpha (TNFα) response following administration to mice when associated with their non-piliated
parent, suggesting that PRL2010 sortase-dependent pili also elicit immunomodulatory activity [55].
The biological significance of this finding may be that triggering TNFα production by pili synthetized
by B. bifidum PRL2010 represents a cross-talk signal by an early colonizer of the human gut [7,14,53,56].
In this framework, it is worth mentioning that TNFα superfamily members are not only connected to
the manifestation of inflammatory diseases [57], but also exert a key role in the rejection of tumors and
the response to infections [58,59]. Furthermore, TNFα induction may be crucial for the establishment
of cross-talk among immune cells and commensal bacteria without causing inflammation or other
harmful effects [60].
In addition, sortase-dependent pili of PRL2010 were shown to promote self-aggregation as well
as aggregation of PRL2010 cells with cells of other gut microorganisms including bifidobacteria and
lactobacilli [55,61]. This suggests that these extracellular proteins are responsible for the generation of
macro-colonies or biofilm in the environment.
Interestingly, the B. bifidum species is the only Bifidobacterium taxon without capsular
polysaccharides genes which seems to be absent due to a recent deletion event [62].
Nevertheless, a small number of isolates of the B. bifidum species have recently been shown
to produce a complex mixture of polysaccharides, i.e., a negatively charged phospho-glycero-β-
galactofuranan (PGβG), four neutral polysaccharides being β-(1-6)-glucan, β-(1-4)-galactan,
β-(1-6)-galactan and β-galactofuranan and finally, starch. Interestingly, these two fractions were shown
to exert distinct immune responses when assayed on dendritic cells. PGβG increased pro-inflammatory
immune responses by enhancing the levels of TNFα, whereas CSGG induced immunosuppressive
regulatory T cells and interleukin-10 [63].
Many enteric bacteria possess the ability to transform bile salts biochemically through the
deconjugation of bile salts via the action of a Bile Salt Hydrolase (BSH). The detergent action of bile
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salts helps in the reduction of intestinal absorption and increased fecal elimination [64], with an overall
hypolipidemic in vivo effect [65]. Recent screening analyses revealed that BSH activity is widely
distributed in many bifidobacterial species (i.e., B. longum subsp. longum, B. longum subsp. infantis,
B. animalis, and B. bifidum) [66,67]. B. bifidum PRL2010 shows noteworthy BSH action on conjugated
secondary bile salts (glycodeoxycholate and taurodeoxycholate) [68,69] in line with what has been
observed in other Bifidobacterium species, such as B. animalis and B. longum [70]. The importance of
this enzyme for microorganisms is also so far not well characterized. In fact, various suppositions
have been suggested, but the specific biological meaning of bile salt hydrolases at this time remains
unidentified. It has been theorized that the conjugation of bile salts may be a tool that bacteria use in
order to produce bile detoxication and thus, these enzymes may exert a key function in microbial bile
tolerance and survival in the human gut [71].
8. The Ecological Role of B. bifidum Species in the Infant Gut Microbiota
As described above, bifidobacteria are amongst the first microbial colonizers of the infant
gut [21]. Upon delivery, the gut environment is subject to massive bacterial colonization, in particular
bifidobacteria, which is acquired through vertical transmission involving direct mother–baby contact
at birth and is supported through breastfeeding [21]. Notably, under “non-natural” conditions, such as
a caesarian delivery or baby feeding with reconstituted or formula milk, the newborn gut may undergo
rapid colonization by environmental microorganisms that normally do not occur at that stage or in
such abundance, which may provoke long lasting health effects on the host [21]. Supplementation of
health-promoting bacteria with, for example, bifidobacteria that are typically found in the infant gut
during this very critical window of time may be crucial in terms of preventing the establishment of an
aberrant microbiota with its associated negative health implications.
In this context, it has been shown that members of the B. bifidum species are able to exert a
cooperative syntrophic effect to benefit other elements of the gut microbiota, particularly with regards
to other members of (healthy) infant-associated bifidobacterial communities [52]. Notably, in vivo
murine experiments involving B. bifidum PRL2010 showed that in contrast to other bifidobacterial
strains like B. longum subsp. infantis ATCC15697 representing another member of the infant gut
microbiota, PRL2010 possesses cross-feeding properties that support the growth of other bifidobacteria
and exhibits a high interaction index, which measures the level of microbe–microbe interaction elicited
by a bacterial strain [52]. The cross-feeding features of B. bifidum PRL2010 have been further analyzed
by in vitro tests aimed at investigating how co-cultivation of PRL2010 cells with other strains is able to
increase the growth abilities of these later as compared to growth yields obtained when these strains
were cultivated independently. Remarkably, the cross-feeding characteristics of B. bifidum PRL2010
were evident when this strain was cultivated on host-derived glycans like mucin or HMOs [72,73]
or on plant-derived carbohydrates such as starch and xylan [74]. In this context, it has been shown
that the metabolism of these complex carbohydrates by PRL2010 causes the release of rather simple
carbohydrates which then become accessible to other members of the (bifido)bacterial community. The
trophic interaction of B. bifidum with other bifidobacterial species and thus its capability to sustain the
growth of other bifidobacteria has recently been highlighted for B. bifidum ATCC 15696—notably, ATCC
15696 hydrolyzes 2’-O-fucosyl-lactose, a major fucosylated HMO, though it does not employ fucose
that is left in the culture broth [75]. Nevertheless, fucose is a growth substrate for Bifidobacterium breve
24b. Notably, the release of fucose by B. bifidum (the donor), thereby allowing the growth of B. breve
(the beneficiary), supports the concept of syntropy [75].
The presence of B. bifidum PRL2010 cells in the murine gut has been shown to provoke an
expansion of the murine gut glycobiome, i.e., the overall genetic arsenal that is involved in carbohydrate
metabolism, toward enzymatic degradation of plant- and host-derived glycans [52].
Another interesting activity of the members of the B. bifidum species in relation to their interaction
with other members of the human gut microbiota, i.e., microbe–microbe cross-talk, is represented by
the ability of strains of this species to produce sortase-dependent pili, particularly when residing in
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their natural ecological niche, the mammalian gut [30,53]. Pili also appear, apart from playing a role in
host interaction as described above, to be crucial for the establishment of physical contacts with other
bifidobacterial/gut commensal cells through cell aggregation [61].
9. Conclusions
Many B. bifidum strains have been described to elicit beneficial effects, including antibacterial
features against pathogens like Helicobacter pylori [76,77], drop of apoptosis in the intestinal mucosa
of premature babies affected by necrotizing enterocolitis [78], modulation of the host-immune
system [79,80], and alleviation of inflammatory activities associated with certain chronic gut
dysfunctions [81,82]. Nevertheless, none of these characteristics have been investigated in any
detail within their natural ecological context, the infant gut. In such an environment, bifidobacterial
cells are expected to drive important functions in terms of priming the immune system, enhancing the
mucus layer, and modulating the establishment of a correct microbiota homeostasis. Nevertheless,
in order to exploit a possible probiotic activity in the human gut, bacterial cells must be viable in
this body-compartment. Furthermore, they should also colonize, compete, and persist in the human
intestine. Thus, B. bifidum probiotic strains need to survive under gastrointestinal challenges [83] and
should be able to colonize the human gut and consequently impact on the intestinal resident microbial
communities. Another notable feature that is shown by human health promoting microorganisms
is their ability to displace and compete with pathogens. In this context, in vitro experiments have
demonstrated that B. bifidum PRL2010 cells strongly inhibit the adhesion of enteropathogens including
Escherichia coli and Cronobacter sakazakii [83], which are frequently implicated in severe gastrointestinal
diseases in infants.
Notably, for most bifidobacterial strains that are currently commercialized as probiotics, little
information is available about the molecular mechanisms supporting their claimed probiotic actions.
Apart from the exploitation of B. bifidum strains as probiotic bacteria for infants, another possible
use of these microorganisms includes the treatment of women during pregnancy. Such a probiotic
administration strategy might be key in order to modulate the mother’s gut engraftment by B. bifidum
cells prior to delivery and, therefore, to assure the establishment of an appropriate bifidobacterial
community that will then be vertically inherited by the newborn. Nonetheless, various clinical testing
involving B. bifidum must be carried out before meaningful probiotic claims (for humans) can be made.
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